Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc‐fused interleukin‐1 receptor antagonist, in healthy subjects: A first‐in‐human study

• Published in: British journal of clinical pharmacology Vol. 86; no. 2; pp. 372 - 379
• Main Authors: Oh, Jaeseong, Huh, Ki Young, Cho, Young‐Gyu, Cha, Ji‐Eun, Kim, Se‐Jin, Yoon, Seo Hyun, Park, Sung Sup, Yoon, Hyunyee, Lee, Jieon, Lee, Howard
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.02.2020
• Subjects: biopharmaceutics; monoclonal antibodies; Original; pharmacodynamics; pharmacokinetics; pharmacokinetics; biopharmaceutics; pharmacodynamics; monoclonal antibodies

Aims We performed a first‐in‐human study with HL2351, a novel hybrid Fc‐fused interleukin (IL)‐1 receptor antagonist, to evaluate its tolerability, pharmacokinetics and pharmacodynamics (PD) after a single subcutaneous (SC) administration in healthy subjects. Methods A randomized, double‐blind, plac...